Nelson Sonja

Chief Fin. & Operating OfficerAmbrx Biopharma Inc. (AMAM) · full profile →Form 4 · filed Jan 31, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
6
0 non-derivative · 6 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 27, 2023Disposed to issuer(D)2.6M0
Jan 27, 2023Grant(A)2.6M2.6M
Jan 27, 2023Disposed to issuer(D)850K0
Jan 27, 2023Grant(A)425K425K
Jan 27, 2023Disposed to issuer(D)425K0
Jan 27, 2023Grant(A)850K850K

Transaction Codes

D
Disposition to the issuer
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-23-005791) within minutes of acceptance. Every field above traces to the original document. Verify it directly: